Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7152760rdf:typepubmed:Citationlld:pubmed
pubmed-article:7152760lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:7152760lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:7152760lifeskim:mentionsumls-concept:C0014544lld:lifeskim
pubmed-article:7152760lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:7152760pubmed:issue6lld:pubmed
pubmed-article:7152760pubmed:dateCreated1983-3-17lld:pubmed
pubmed-article:7152760pubmed:abstractTextThirty-two patients with epilepsy were typed for 26 HLA-A, -B and -C antigens. Sixteen of the patients were treated with phenytoin. They all had serum IgA concentrations below 0.20 g/l. Another 16 patients received carbamazepine. This group had showed a marked decrease of IgA and IgM serum concentrations during their first month of carbamazepine monotherapy. Among those who showed an IgA deficiency during phenytoin treatment, 14 had the antigen HLA-A2. The frequency of HLA-A2 was similar between controls and patients who had reduced immunoglobulin levels after 1 month of carbamazepine treatment.lld:pubmed
pubmed-article:7152760pubmed:languageenglld:pubmed
pubmed-article:7152760pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:citationSubsetIMlld:pubmed
pubmed-article:7152760pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7152760pubmed:statusMEDLINElld:pubmed
pubmed-article:7152760pubmed:issn0192-0561lld:pubmed
pubmed-article:7152760pubmed:authorpubmed-author:ThorsbyEElld:pubmed
pubmed-article:7152760pubmed:authorpubmed-author:AarliJ AJAlld:pubmed
pubmed-article:7152760pubmed:authorpubmed-author:GilhusN ENElld:pubmed
pubmed-article:7152760pubmed:issnTypePrintlld:pubmed
pubmed-article:7152760pubmed:volume4lld:pubmed
pubmed-article:7152760pubmed:ownerNLMlld:pubmed
pubmed-article:7152760pubmed:authorsCompleteYlld:pubmed
pubmed-article:7152760pubmed:pagination517-20lld:pubmed
pubmed-article:7152760pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:meshHeadingpubmed-meshheading:7152760-...lld:pubmed
pubmed-article:7152760pubmed:year1982lld:pubmed
pubmed-article:7152760pubmed:articleTitleHLA antigens in epileptic patients with drug-induced immunodeficiency.lld:pubmed
pubmed-article:7152760pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7152760pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7152760pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7152760lld:pubmed